Selective hydroxamate-based ADAM10 inhibitors (LT4 and MN8) reduce Hodgkin lymphoma cell growth, inhibit CD30 and TNFα shedding, and enhance the anti-tumour activity of brentuximab vedotin in 3D culture models that mimic the lymph node microenvironment, highlighting their potential for combinatory therapy development [154]. The gene discussed is ADAM10; the disease is neoplasm.